Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673425 | 0.98 | MEN1 (0.47) | MEN1KMT2AALDH1A1NAMPTRECQL | |
| SCHEMBL13226885 | 0.95 | MEN1 (0.44) | MEN1KMT2AALDH1A1NAMPTRECQL | |
| SCHEMBL19261639 | 0.93 | MEN1 (0.45) | MEN1KMT2AALDH1A1RECQLTSHR | |
| SCHEMBL23518687 | 0.90 | MEN1 (0.46) | MEN1KMT2AALDH1A1NAMPTRECQL | |
| SCHEMBL23677003 | 0.90 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1NAMPTSPR | |
| SCHEMBL13226876 | 0.89 | MEN1 (0.48) | MEN1KMT2AALDH1A1RECQLTSHR | |
| SCHEMBL13684293 | 0.89 | EPHX2 (0.43) | MEN1KMT2AALDH1A1NAMPTRECQL | |
| SCHEMBL18199506 | 0.88 | MEN1 (0.52) | MEN1KMT2AALDH1A1RECQLTSHR | |
| SCHEMBL15255244 | 0.88 | MEN1 (0.52) | MEN1KMT2AALDH1A1RECQLTSHR | |
| SCHEMBL10304153 | 0.88 | MEN1 (0.56) | MEN1KMT2AALDH1A1RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.